Celecoxib

Generic Name
Celecoxib
Brand Names
Celebrex, Elyxyb, Seglentis
Drug Type
Small Molecule
Chemical Formula
C17H14F3N3O2S
CAS Number
169590-42-5
Unique Ingredient Identifier
JCX84Q7J1L
Background

Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon...

Indication

Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
...

Associated Conditions
Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
Associated Therapies
-
Clinical Trials
Related News

Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis

First Posted Date
2019-04-11
Last Posted Date
2024-12-17
Lead Sponsor
National Institute of Mental Health (NIMH)
Target Recruit Count
111
Registration Number
NCT03912428
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Open-Label CA-008 (Vocacapsaicin) in Bunionectomy

First Posted Date
2019-03-21
Last Posted Date
2021-10-27
Lead Sponsor
Concentric Analgesics
Target Recruit Count
36
Registration Number
NCT03885596
Locations
🇺🇸

Lotus Clinical Research, LLC, Pasadena, California, United States

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1
Terminated
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Anatomic Stage IV Breast Cancer AJCC v8
Anemia
Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Castration-Resistant Prostate Carcinoma
Interventions
Drug: Abemaciclib
Drug: Abiraterone
Drug: Afatinib
Biological: Bevacizumab
Drug: Bicalutamide
Procedure: Biospecimen Collection
Drug: Bortezomib
Drug: Cabazitaxel
Drug: Cabozantinib
Drug: Capecitabine
Drug: Carboplatin
Drug: Celecoxib
Drug: Cobimetinib
Drug: Copanlisib
Drug: Dabrafenib
Drug: Dacomitinib
Drug: Darolutamide
Drug: Dasatinib
Drug: Doxorubicin
Biological: Durvalumab
Drug: Enasidenib
Drug: Entrectinib
Drug: Enzalutamide
Drug: Erlotinib
Drug: Everolimus
Drug: Fluorouracil
Drug: Idelalisib
Drug: Imatinib
Biological: Ipilimumab
Drug: Lenvatinib
Drug: Leucovorin
Drug: Lorlatinib
Drug: Losartan
Drug: Nab-paclitaxel
Drug: Neratinib
Biological: Nivolumab
Drug: Olaparib
Drug: Oxaliplatin
Drug: Palbociclib
Drug: Panobinostat
Biological: Pembrolizumab
Biological: Pertuzumab
Drug: Ponatinib
Other: Quality-of-Life Assessment
Drug: Regorafenib
Drug: Ruxolitinib
Drug: Sirolimus
Drug: Sorafenib
Drug: Sunitinib
Drug: Trametinib
Biological: Trastuzumab Emtansine
Drug: Tretinoin
Drug: Vemurafenib
Drug: Venetoclax
Drug: Vismodegib
Drug: Vorinostat
First Posted Date
2019-03-18
Last Posted Date
2024-03-04
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
2
Registration Number
NCT03878524
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Efficacy of Opioid-limiting Pain Management Protocol in Men Undergoing Urethroplasty

First Posted Date
2019-03-01
Last Posted Date
2023-08-01
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
60
Registration Number
NCT03859024
Locations
🇺🇸

University of Alabama of Birmingham, Birmingham, Alabama, United States

Nonopioid Analgesia After Labral Surgery

First Posted Date
2019-01-31
Last Posted Date
2019-01-31
Lead Sponsor
Henry Ford Health System
Target Recruit Count
100
Registration Number
NCT03825809
Locations
🇺🇸

Henry Ford Health System, Detroit, Michigan, United States

Clinical Study to Evaluate Effect on QT/QTc Interval After Multiple Dose of Celecoxib

First Posted Date
2019-01-30
Last Posted Date
2019-01-30
Lead Sponsor
Samsung Medical Center
Target Recruit Count
28
Registration Number
NCT03822520
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

Nonopioid Analgesia After Arthroscopic Meniscus Surgery

First Posted Date
2019-01-29
Last Posted Date
2023-12-05
Lead Sponsor
Henry Ford Health System
Target Recruit Count
61
Registration Number
NCT03820193
Locations
🇺🇸

Henry Ford Health System, Detroit, Michigan, United States

Nonopioid Analgesia After Anterior Cruciate Ligament Reconstruction

First Posted Date
2019-01-28
Last Posted Date
2021-02-11
Lead Sponsor
Henry Ford Health System
Target Recruit Count
62
Registration Number
NCT03818932
Locations
🇺🇸

Henry Ford Health System, Detroit, Michigan, United States

Nonopioid Analgesia After Rotator Cuff Repair

First Posted Date
2019-01-28
Last Posted Date
2024-04-02
Lead Sponsor
Henry Ford Health System
Target Recruit Count
70
Registration Number
NCT03818919
Locations
🇺🇸

Health Ford Health System, Detroit, Michigan, United States

Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

First Posted Date
2018-07-26
Last Posted Date
2023-07-18
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
8
Registration Number
NCT03599453
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy